DrugPatentWatch Database Preview
RASUVO Drug Profile
Email this page to a colleague
Which patents cover Rasuvo, and when can generic versions of Rasuvo launch?
Rasuvo is a drug marketed by Medexus and is included in one NDA. There is one patent protecting this drug.
This drug has twenty-nine patent family members in twenty-one countries.
The generic ingredient in RASUVO is methotrexate. There are twenty drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the methotrexate profile page.
DrugPatentWatch® Generic Entry Outlook for Rasuvo
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be June 1, 2029. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for RASUVO
| International Patents: | 29 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 133 |
| Clinical Trials: | 2 |
| Patent Applications: | 4,332 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for RASUVO |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for RASUVO |
| What excipients (inactive ingredients) are in RASUVO? | RASUVO excipients list |
| DailyMed Link: | RASUVO at DailyMed |
DrugPatentWatch® Estimated Generic Entry Opportunity Date for RASUVO
Generic Entry Date for RASUVO*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;SUBCUTANEOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for RASUVO
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Vanderbilt University | Phase 1 |
| Pfizer | Phase 1 |
| Virginia Commonwealth University | Phase 1 |
Pharmacology for RASUVO
| Drug Class | Folate Analog Metabolic Inhibitor |
| Mechanism of Action | Folic Acid Metabolism Inhibitors |
US Patents and Regulatory Information for RASUVO
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medexus | RASUVO | methotrexate | SOLUTION;SUBCUTANEOUS | 205776-001 | Jul 10, 2014 | RX | Yes | Yes | Get Started Free | Get Started Free | Get Started Free | ||||
| Medexus | RASUVO | methotrexate | SOLUTION;SUBCUTANEOUS | 205776-007 | Jul 10, 2014 | RX | Yes | Yes | Get Started Free | Get Started Free | Get Started Free | ||||
| Medexus | RASUVO | methotrexate | SOLUTION;SUBCUTANEOUS | 205776-004 | Jul 10, 2014 | RX | Yes | Yes | Get Started Free | Get Started Free | Get Started Free | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for RASUVO
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 2009544636 | Get Started Free |
| Montenegro | 01940 | Get Started Free |
| Russian Federation | 2009106053 | Get Started Free |
| >Country | >Patent Number | >Estimated Expiration |
